Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Depreciation & Amortization (CF) of $188000.0 for Q1 2026, up 14.63% on a YoY basis from $164000.0 in Q1 2025, and up 1.08% quarter-over-quarter from $186000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $188000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 14.63% year-over-year to $188000.0; the trailing twelve-month figure through Mar 2026 stood at $723000.0 (up 20.9% YoY), and the FY2025 full-year result was $699000.0, up 19.08% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $188000.0, up from $186000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $188000.0 in Q1 2026, with the low at $138000.0 in Q1 2023.
- Historically, Depreciation & Amortization (CF) has averaged $154000.0 across 5 years, with a median of $146000.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) retreated 13.79% — and 2025, when it advanced 26.24%.
- Lineage Cell Therapeutics' Depreciation & Amortization (CF) stood at $141000.0 in 2022, then increased by 1.42% to $143000.0 in 2023, then grew by 5.59% to $151000.0 in 2024, then advanced by 23.18% to $186000.0 in 2025, then advanced by 1.08% to $188000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $188000.0 (Q1 2026), $186000.0 (Q4 2025), and $178000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | 188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Sep 30, 2025 | 178,000.00 |
| Sep 30, 2025 | 178,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Mar 31, 2025 | 164,000.00 |
| Mar 31, 2025 | 164,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Sep 30, 2024 | 141,000.00 |
| Sep 30, 2024 | 141,000.00 |
| Jun 30, 2024 | 142,000.00 |
| Jun 30, 2024 | 142,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Dec 31, 2023 | 143,000.00 |